These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 14688082

  • 1. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.
    Li X, Lockatell CV, Johnson DE, Lane MC, Warren JW, Mobley HL.
    Infect Immun; 2004 Jan; 72(1):66-75. PubMed ID: 14688082
    [Abstract] [Full Text] [Related]

  • 2. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M, Asadi Karam MR, Shokrgozar MA, Oloomi M, Jafari A, Bouzari S.
    Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.
    Li X, Erbe JL, Lockatell CV, Johnson DE, Jobling MG, Holmes RK, Mobley HL.
    Infect Immun; 2004 Dec; 72(12):7306-10. PubMed ID: 15557656
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections.
    Asadi Karam MR, Shirzad AM, Habibi M, Bouzari S.
    Int Immunopharmacol; 2018 May; 58():40-47. PubMed ID: 29549718
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nasal immunization with attenuated Salmonella Typhimurium expressing an MrpA-TetC fusion protein significantly reduces Proteus mirabilis colonization in the mouse urinary tract.
    Scavone P, Umpiérrez A, Maskell DJ, Zunino P.
    J Med Microbiol; 2011 Jul; 60(Pt 7):899-904. PubMed ID: 21415205
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein.
    Scavone P, Umpiérrez A, Rial A, Chabalgoity JA, Zunino P.
    Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.
    Alamuri P, Eaton KA, Himpsl SD, Smith SN, Mobley HL.
    Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract.
    Zhao H, Li X, Johnson DE, Blomfield I, Mobley HL.
    Mol Microbiol; 1997 Mar; 23(5):1009-19. PubMed ID: 9076737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.